We are live on ! Find out more
AI

Allostery Investments Portfolio holdings

AUM $7.85M
This Fund
S&P 500
This Quarter Est. Return
+35.03%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$7.85M
AUM Growth
-$61.5M
Cap. Flow
-$62.1M
Cap. Flow %
-791.46%
Top 10 Hldgs %
82.66%
Holding
46
New
5
Increased
1
Reduced
14
Closed
26

Top Buys

Rank Stock Value
1
RZLT icon
Rezolute
RZLT
+$443K
2
FULC icon
Fulcrum Therapeutics
FULC
+$216K
3
AKRO
Akero Therapeutics
AKRO
+$204K
4
TRML
Tourmaline Bio
TRML
+$152K
5
TNGX icon
Tango Therapeutics
TNGX
+$98.9K

Top Sells

Rank Stock Value
1
ABVX
Abivax
ABVX
+$6.08M
2
MRUS
Merus
MRUS
+$5.44M
3
KALV
KalVista Pharmaceuticals
KALV
+$5.11M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$4.18M
5
APGE icon
Apogee Therapeutics
APGE
+$3.96M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELDN icon
26
Eledon Pharmaceuticals
ELDN
$276M
– –
-100,000
Closed -$339K
ETNB
27
DELISTED
89bio
ETNB
– –
-25,000
Closed -$182K
EWTX icon
28
Edgewise Therapeutics
EWTX
$4.39B
– –
-3,000
Closed -$66K
GOSS icon
29
Gossamer Bio
GOSS
$66.5M
– –
-613,028
Closed -$674K
INSM icon
30
Insmed
INSM
$23.2B
– –
-10,000
Closed -$763K
IONS icon
31
Ionis Pharmaceuticals
IONS
$9.35B
– –
-35,000
Closed -$1.06M
LXEO icon
32
Lexeo Therapeutics
LXEO
$366M
– –
-5,054
Closed -$17.5K
MDGL icon
33
Madrigal Pharmaceuticals
MDGL
$12.6B
– –
-600
Closed -$199K
PCVX icon
34
Vaxcyte
PCVX
$7.89B
– –
-32,000
Closed -$1.21M
PHGE icon
35
BiomX
PHGE
$2.04M
– –
-49,507
Closed -$523K
PLRX icon
36
Pliant Therapeutics
PLRX
$67.5M
– –
-441,686
Closed -$596K
RLYB icon
37
Rallybio
RLYB
$86.6M
– –
-94,029
Closed -$492K
SLNO
38
DELISTED
Soleno Therapeutics
SLNO
– –
-20,000
Closed -$1.43M
SWTX
39
DELISTED
SpringWorks Therapeutics
SWTX
– –
-52,500
Closed -$2.32M
TARS icon
40
Tarsus Pharmaceuticals
TARS
$2.56B
– –
-13,600
Closed -$699K
VIR icon
41
Vir Biotechnology
VIR
$1.47B
– –
-22,202
Closed -$144K
WVE icon
42
Wave Life Sciences
WVE
$1.12B
– –
-17,500
Closed -$141K
XENE icon
43
Xenon Pharmaceuticals
XENE
$6.32B
– –
-30,000
Closed -$1.01M
ZURA icon
44
Zura Bio
ZURA
$497M
– –
-2,329,384
Closed -$3M
ORKA
45
Oruka Therapeutics
ORKA
$5.56B
– –
-20,000
Closed -$205K
CLYM
46
Climb Bio
CLYM
$735M
– –
-244,988
Closed -$299K
1
2

Similar funds

CP
Castalian Partners Excelsior, Minnesota $7.36M AUM
CAWM
Capital A Wealth Management New Castle, Pennsylvania $8.94M AUM
ADIM
Alpha DNA Investment Management Columbia, Maryland $8.98M AUM 26.05% 1-Year Est. Return
PC
Prysm Capital Princeton, New Jersey $10.6M AUM 2.38% 1-Year Est. Return
AVM
Altos Ventures Management Burlingame, California $11.7M AUM 182.72% 1-Year Est. Return
NP
Newlight Partners New York $3.9M AUM 96.05% 1-Year Est. Return
BPWM
Black Point Wealth Management Naples, Florida $3.5M AUM 16.42% 1-Year Est. Return
CSD
Clear Street Derivatives New York $12.4M AUM 1.7% 1-Year Est. Return

Allostery Investments's Q2 2025 Portfolio in Review

As of Q2 2025, Allostery Investments held 46 positions worth $7.85M, down 89% from $69.3M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Allostery Investments withdrew a net $62.1M in Q2 2025, closing 26 positions and reducing 14 holdings. Its most notable exit was Alkermes, an estimated $3.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Allostery Investments opened a new position in Rezolute worth $532K.

  • Allostery Investments's largest Q2 2025 buy was Rezolute: 119,294 shares worth $532K.
  • Allostery Investments added most to Akero Therapeutics in Q2 2025, an estimated $204K increase.
  • Allostery Investments's biggest Q2 2025 reduction was Abivax, cutting an estimated $6.08M.
  • Allostery Investments fully exited Alkermes in Q2 2025, selling an estimated $3.8M.
  • Allostery Investments's ten largest holdings make up 83% of its $7.85M portfolio in Q2 2025.
  • Allostery Investments opened 5 new positions and closed 26 in Q2 2025.
  • Allostery Investments's portfolio value fell 89% quarter-over-quarter to $7.85M.

Based on Allostery Investments's 13F filing for Q2 2025, filed 14 Aug 2025.